September 21, 2016Letter Agreement • September 23rd, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This letter agreement (the “Letter Agreement”) confirms that your employment with Enumeral Biomedical Holdings, Inc. (with its subsidiaries, the “Company”) has ceased effective September 21, 2016 and sets forth the terms of your separation from service as an employee of the Company. In this Letter Agreement, reference is occasionally made to the Amended and Restated Employment Agreement, dated as of July 21, 2014, between you and Enumeral Biomedical Corp., a subsidiary of the Company, as assumed by the Company on July 31, 2014 (the “Amended Employment Agreement”). In consideration of resolving any and all disputes as to whether your employment termination was for or without Cause, as that term is defined in the Amended Employment Agreement, the Company is providing you with the compensation and benefits specified herein in consideration for your execution of this Letter Agreement.
AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • September 23rd, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Amendment”), is dated as of September 21, 2016, by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (with its subsidiaries, the “Company”), and Barry Buckland, Ph.D. (the “Advisor”). This Amendment amends that certain Scientific Advisory Board Agreement, dated as of September 14, 2014, by and between the Company and the Advisor (the “SAB Agreement”). Capitalized words used but not otherwise defined herein shall have the meanings ascribed to such terms in the SAB Agreement.
